Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780648 | 0.80 | LDHA (0.45) | ELANESMN1; SMN2KMT2AHTTTDP1 | |
| SCHEMBL21477388 | 0.79 | LDHA (0.47) | ELANESMN1; SMN2KMT2AHTTTDP1 | |
| SCHEMBL21477395 | 0.79 | NPC1 (0.55) | ELANESMN1; SMN2KMT2ANPC1MAPT | |
| SCHEMBL21477407 | 0.79 | ABL1 (0.47) | ELANESMN1; SMN2KMT2ANPC1MAPT | |
| SCHEMBL6590103 | 0.78 | LMNA (0.57) | ELANECYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL29177459 | 0.78 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL19780744 | 0.77 | TP53 (0.49) | ELANESMN1; SMN2KMT2ANPC1TP53 | |
| SCHEMBL13458077 | 0.77 | LMNA (0.56) | ELANECYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL21477355 | 0.76 | NPC1 (0.55) | ELANECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21480916 | 0.76 | TRPV1 (0.46) | CYP1A2CYP2D6CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| EP-3484868-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| US-20190315787-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| WO-2018011186-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315787-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | ELANE 931/4885CYP1A2 3726/4885CYP2D6 2610/4885 |
| US-11713332-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | ELANE 931/4885CYP1A2 3726/4885CYP2D6 2610/4885 |
| US-20230322826-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | ELANE 931/4885CYP1A2 3726/4885CYP2D6 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.